JP2021531276A5 - - Google Patents

Info

Publication number
JP2021531276A5
JP2021531276A5 JP2021502545A JP2021502545A JP2021531276A5 JP 2021531276 A5 JP2021531276 A5 JP 2021531276A5 JP 2021502545 A JP2021502545 A JP 2021502545A JP 2021502545 A JP2021502545 A JP 2021502545A JP 2021531276 A5 JP2021531276 A5 JP 2021531276A5
Authority
JP
Japan
Prior art keywords
human
idua
expression vector
immunosuppressive therapy
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021502545A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531276A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/042205 external-priority patent/WO2020018665A1/en
Publication of JP2021531276A publication Critical patent/JP2021531276A/ja
Publication of JP2021531276A5 publication Critical patent/JP2021531276A5/ja
Priority to JP2024040767A priority Critical patent/JP2024095680A/ja
Pending legal-status Critical Current

Links

JP2021502545A 2018-07-18 2019-07-17 完全ヒトグリコシル化ヒトα−L−イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療 Pending JP2021531276A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024040767A JP2024095680A (ja) 2018-07-18 2024-03-15 完全ヒトグリコシル化ヒトα-L-イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862699923P 2018-07-18 2018-07-18
US62/699,923 2018-07-18
PCT/US2019/042205 WO2020018665A1 (en) 2018-07-18 2019-07-17 Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idus)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024040767A Division JP2024095680A (ja) 2018-07-18 2024-03-15 完全ヒトグリコシル化ヒトα-L-イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療

Publications (2)

Publication Number Publication Date
JP2021531276A JP2021531276A (ja) 2021-11-18
JP2021531276A5 true JP2021531276A5 (cg-RX-API-DMAC7.html) 2022-07-26

Family

ID=69164759

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021502545A Pending JP2021531276A (ja) 2018-07-18 2019-07-17 完全ヒトグリコシル化ヒトα−L−イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療
JP2024040767A Pending JP2024095680A (ja) 2018-07-18 2024-03-15 完全ヒトグリコシル化ヒトα-L-イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024040767A Pending JP2024095680A (ja) 2018-07-18 2024-03-15 完全ヒトグリコシル化ヒトα-L-イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療

Country Status (10)

Country Link
US (1) US20210275647A1 (cg-RX-API-DMAC7.html)
EP (1) EP3823590A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021531276A (cg-RX-API-DMAC7.html)
KR (1) KR20210034037A (cg-RX-API-DMAC7.html)
AU (1) AU2019306236A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021000830A2 (cg-RX-API-DMAC7.html)
CA (1) CA3106651A1 (cg-RX-API-DMAC7.html)
IL (1) IL280198B2 (cg-RX-API-DMAC7.html)
SG (1) SG11202100423YA (cg-RX-API-DMAC7.html)
WO (1) WO2020018665A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3068328A1 (en) 2017-07-06 2019-01-10 The Trustees Of The University Of Pennsylvania Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
EP3684938A1 (en) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
US20190114858A1 (en) * 2017-10-16 2019-04-18 Raritan Americas, Inc. System for controlling access to an equipment rack and intelligent power distribution unit and control unit used therein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
CA2486584A1 (en) * 2002-06-07 2003-12-18 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
US8114627B2 (en) * 2006-09-21 2012-02-14 The Scripps Research Institute Genetically programmed expression of selectively sulfated proteins in eubacteria
EP3230438B1 (en) * 2014-12-12 2024-12-04 University of Copenhagen N-glycosylation
KR20220082100A (ko) * 2015-05-15 2022-06-16 리젠츠 오브 더 유니버시티 오브 미네소타 중추 신경계로의 아데노-연관 치료적 전달
MA43968A (fr) * 2016-02-03 2018-12-12 Univ Pennsylvania Thérapie génique pour traiter la mucopolysaccharidose de type i
HRP20231451T1 (hr) * 2016-02-05 2024-03-01 Emory University Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu
IL309808B2 (en) * 2016-11-15 2025-04-01 Univ Minnesota Method for improving neurological function in MPSI and MPSII and other neurological disorders
JP2020508289A (ja) * 2017-01-31 2020-03-19 レジェンクスバイオ インコーポレーテッド 完全ヒトグリコシル化ヒトα−L−イズロニダーゼ(IDUA)を用いたムコ多糖症I型の治療

Similar Documents

Publication Publication Date Title
JP2020508289A5 (cg-RX-API-DMAC7.html)
US12329812B2 (en) Nucleic acid vaccines
JP6896050B2 (ja) TATk−CDKL5融合タンパク質、組成物、製剤、及びそれらの使用
KR20230154048A (ko) Sbi 어쥬번트를 포함하는 조성물 및 이들의 이용 방법
US11274158B2 (en) Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
US20200360364A1 (en) Methods and compositions for treating inflammatory or autoimmune diseases or conditions using chrna6 activators
TW202222821A (zh) 用於預防及/或治療covid-19之組合物及方法
JP2017052783A5 (cg-RX-API-DMAC7.html)
JP2019522989A (ja) TATκ−CDKL5融合タンパク質、組成物、製剤、及びそれらの使用
JP2024095680A5 (cg-RX-API-DMAC7.html)
JP2023511382A5 (cg-RX-API-DMAC7.html)
Madrigal et al. Regulation of MCP‐1 production in brain by stress and noradrenaline‐modulating drugs
KR102129007B1 (ko) 수면장애에 의해 유발되는 학습 및 기억 장애 치료용 약학적 조성물
AU2022233960A1 (en) Alpha-1-antitrypsin (aat) in the treatment and/or prevention of neurological disorders
Xie et al. Atopic dermatitis: updated insights into pathophysiology and emerging therapies
KR20210078428A (ko) 중추신경계 통증신호 제어를 통한 암유발 통증 완화 방법
US20260035408A1 (en) WKYMVm peptide analogues having six residues and uses thereof
Crosson et al. Heather Melichar
WO2023201133A1 (en) Cell therapy for alzheimer's disease
Yang et al. Progress in Mechanism of E. coli K1 Crossing the Blood-brain Barrier
Tayebati et al. (Neuro) transmitter systems in circulating immune cells: a target of immunopharmacological interventions?
HK40072892A (en) Nucleic acid vaccines
HK40076592A (en) Nucleic acid vaccines
CN119280206A (zh) 精胺在制备抗抑郁药中的应用
CA3107232A1 (en) Compositions and methods for the prevention and/or treatment of covid-19